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Dear Editor, 
During the period 1997-2015 we observed 200 
patients with hookworm-related cutaneous larva 
migrans (HrCLM) acquired in Tropical or Subtropical 
countries. For all these patients we collected complete 
data (race, sex, age, country of infestation, location and 
morphology of the lesions, symptoms and therapy). 
Most patients were Caucasians, of both genders, with 
an age ranging from 25 to 60 years. HrCLM was more 
frequently acquired in Brazil and presented with more 
or less numerous and pruritic tracks. Oral albendazole 
was successfully used in most patients. The recent 
observation of our 201st patient prompted us to make a 
short review of the literature about this disease. 
The patient was a 52-year-old Caucasian female 
who contracted the infestation in December 2015 
during a tour in Brazil. The infestation was 
characterized by multiple, erythematous, slightly 
raised, pruritic tracks located on the left breast and back 
(Figure 1). The patient was successfully treated with 
oral albendazole (400 mg/day for seven days).  
HrCLM is an infestation caused by penetration and 
migration of larvae of nematodes in the epidermis. 
Ancylostoma braziliense and Ancylostoma caninum are 
the species most frequently involved. Natural reservoirs 
of these ancylostomas are the stomach and bowel of cats 
and dogs. The natural environment of the larvae is the 
sandy, warm, damp soil. 
HrCLM is characterized by erythematous and 
slightly raised tracks: they may be single or multiple, 
linear or, more frequently, serpiginous, ramified and 
intertwined. The length of tracks is variable (sometimes 
several cm); the width ranges from 1 to 4 mm. Tracks 
are often accompanied by pruritus. The feet and ankles 
are most frequently involved; other locations are the 
legs, knees, buttocks, abdomen and back [1]. 
HrCLM was first described in 1874 by Lee who 
named this dermatitis as a “creeping eruption” [2]. 
According to Muhleisen, in 1893 Crocker used, the 
term of “larva migrans” for the first time. However, he 
thought it was caused by insect larvae [3]. In 1926, 
Kirby Smith et al. [4] discovered in four patients’ larvae 
of a nematode, that they named Agamonematodum 
migrans.  
In 1928, White and Dove [5] demonstrated that third 
stage Ancylostoma braziliense larvae were responsible 
for the disease.  
In 1929, the same authors [6] also demonstrated that 
Ancylostoma caninum larvae could cause creeping 
eruption. 
With time, HrCLM has been referred to in 
numerous ways, such as dermatite linéaire rampante, 
epidermitis linearis migrans, ground itch, larbish, 
sandworm eruption, and sandworm disease as well as 
water dermatitis. Its current name is HrCLM. HrCLM 
is sometimes an occupational disease, for which the 
names of duckhunters’ itch and plumber’s itch were 
suggested. 
HrCLM is endemic in three geographical areas: 
East Africa, Thailand and America (South-East United 
States, the Caribbean and Brazil). However, the 
observation of autochthonous cases in European 
countries is more frequent than in the past: HrCLM has 
been observed in United Kingdom [7], Germany [8], 
France [9] and Italy [10]. The first autochthonous Italian 
case was published in 1977 (a 34-year-old woman from 
Calabria, Southern Italy) [10]. The first Italian pediatric 
case was published in 1988: a 3-year-old male child 
who lived in Cagliari (Sardinia) [11]. 
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Outbreaks of HrCLM were recorded in Nigeria, 
South Africa, Barbados, Belize and France. In 2002, the 
first autochthonous Italian outbreak was recorded in 
Naples [12]. 
Finally, the first study on epiluminescence 
microscopy was published in 2000 [13]. 
HrCLM may be a self-limiting infestation: usually, 
its duration ranges from 2 to 8 weeks. However, a rare 
variety of “chronic” or “persistent” HrCLM, 
characterized by a typical clinical presentation of long 
duration (from 5 to 14 months) has been described [14]. 
The therapy of HrCLM is currently based on 
cryotherapy [15], topical drugs (thiabendazole [16] and 
albendazole [17]), and oral drugs (thiabendazole [18], 
albendazole [19] and ivermectin [20]). The use of ethyl 
chloride [21] and oral diethylcarbamazine [22], 
stibanose [23], chloroquine [24], gamma-
esachlorcycloexan [25], fluoromebendazole [26] and 
mebendazole [27] has been abandoned.  
Cryotherapy can be used in single and small lesions. 
However, it is often ineffective; in addition, it can 
induce the formation of blisters, erosions, ulcers and 
scars [15].  
Topical thiabendazole has been used in different 
concentrations (from 10 to 50%), once-three times/day, 
for 3 to 15 days. It is effective and safe. It may be also 
considered for children [16].  
Literature data on topical albendazole is limited to 
a small number of patients, in whom it was used at a 
concentration of 10%, as a lotion or ointment [17]. 
Oral thiabendazole is effective. However, the daily 
dosage (20, 25 or 50 mg/kg/ day?) and the length of the 
therapy (1, 3 or 4 days?) have not yet established. 
Furthermore, side effects (nausea, abdominal pain, 
vomiting, headache, dizziness, hematuria) are rather 
common and sometimes severe [18].  
Oral albendazole is used at the dosage of 400 
mg/day for 1 to 7 days [19]. Regimens of 1, 3 or 5 days 
are often followed by partial remission or recurrence of 
the infestation [28, 29, 30]. A one-week duration allows 
a complete remission in almost all patients [28; 29; 30]. 
Side effects (nausea, abdominal pain, Herxheimer-like 
reaction, alopecia, Stevens-Johnson syndrome) are rare, 
mild in severity and self-healing [31]. 
Oral ivermectin is also effective. It can be used as a 
single dose, although 2-3 courses are sometimes 
necessary [20]. In several countries, ivermectin is on the 
market, yet only for use in veterinary medicine. On the 
other hand, 1% ivermectin cream seems to be 
ineffective [32]. 
We would recommend cryotherapy or topical 
thiabendazole only for single and small lesions, and oral 
albendazole (for one week) or ivermectin for 
widespread or chronic lesions or those lesions that 
showed to be resistant to cryotherapy or topical 
thiabendazole. 
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